Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

M. G. della Porta, C. H. Jackson, E. P. Alessandrino, M. Rossi, A. Bacigalupo, M. T. van Lint, M. Bernardi, B. Allione, A. Bosi, S. Guidi, V. Santini, L. Malcovati, M. Ubezio, C. Milanesi, E. Todisco, M. T. Voso, P. Musto, F. Onida, A. P. Iori, R. CerrettiG. Grillo, A. Molteni, P. Pioltelli, L. Borin, E. Angelucci, E. Oldani, S. Sica, C. Pascutto, V. Ferretti, A. Santoro, F. Bonifazi, M. Cazzola, A. Rambaldi

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the benefit of cytoreduction before transplant in high-risk patients. We carried out a decision analysis on 1728 MDS who received supportive care, transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised International Prognostic Scoring System (IPSS-R). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of different treatment policies on survival. Life expectancy increased when transplantation was delayed from the initial stages to intermediate IPSS-R risk (gain-of-life expectancy 5.3, 4.7 and 2.8 years for patients aged ⩽55, 60 and 65 years, respectively), and then decreased for higher risks. Modeling decision analysis on IPSS-R versus original IPSS changed transplantation policy in 29% of patients, resulting in a 2-year gain in life expectancy. In advanced stages, HMAs given before transplant is associated with a 2-year gain-of-life expectancy, especially in older patients. These results provide a preliminary evidence to maximize the effectiveness of allo-SCT in MDS.Leukemia advance online publication, 7 April 2017; doi:10.1038/leu.2017.88.

Original languageEnglish
Pages (from-to)2449-2457
Number of pages9
JournalLeukemia
Volume31
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint

Decision Support Techniques
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Life Expectancy
Transplantation
Transplants
Publications
Leukemia
Morbidity
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. / della Porta, M. G.; Jackson, C. H.; Alessandrino, E. P.; Rossi, M.; Bacigalupo, A.; van Lint, M. T.; Bernardi, M.; Allione, B.; Bosi, A.; Guidi, S.; Santini, V.; Malcovati, L.; Ubezio, M.; Milanesi, C.; Todisco, E.; Voso, M. T.; Musto, P.; Onida, F.; Iori, A. P.; Cerretti, R.; Grillo, G.; Molteni, A.; Pioltelli, P.; Borin, L.; Angelucci, E.; Oldani, E.; Sica, S.; Pascutto, C.; Ferretti, V.; Santoro, A.; Bonifazi, F.; Cazzola, M.; Rambaldi, A.

In: Leukemia, Vol. 31, No. 11, 2017, p. 2449-2457.

Research output: Contribution to journalArticle

della Porta, MG, Jackson, CH, Alessandrino, EP, Rossi, M, Bacigalupo, A, van Lint, MT, Bernardi, M, Allione, B, Bosi, A, Guidi, S, Santini, V, Malcovati, L, Ubezio, M, Milanesi, C, Todisco, E, Voso, MT, Musto, P, Onida, F, Iori, AP, Cerretti, R, Grillo, G, Molteni, A, Pioltelli, P, Borin, L, Angelucci, E, Oldani, E, Sica, S, Pascutto, C, Ferretti, V, Santoro, A, Bonifazi, F, Cazzola, M & Rambaldi, A 2017, 'Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System', Leukemia, vol. 31, no. 11, pp. 2449-2457. https://doi.org/10.1038/leu.2017.88
della Porta, M. G. ; Jackson, C. H. ; Alessandrino, E. P. ; Rossi, M. ; Bacigalupo, A. ; van Lint, M. T. ; Bernardi, M. ; Allione, B. ; Bosi, A. ; Guidi, S. ; Santini, V. ; Malcovati, L. ; Ubezio, M. ; Milanesi, C. ; Todisco, E. ; Voso, M. T. ; Musto, P. ; Onida, F. ; Iori, A. P. ; Cerretti, R. ; Grillo, G. ; Molteni, A. ; Pioltelli, P. ; Borin, L. ; Angelucci, E. ; Oldani, E. ; Sica, S. ; Pascutto, C. ; Ferretti, V. ; Santoro, A. ; Bonifazi, F. ; Cazzola, M. ; Rambaldi, A. / Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. In: Leukemia. 2017 ; Vol. 31, No. 11. pp. 2449-2457.
@article{ff8da419107342358710d6ed016ae839,
title = "Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the benefit of cytoreduction before transplant in high-risk patients. We carried out a decision analysis on 1728 MDS who received supportive care, transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised International Prognostic Scoring System (IPSS-R). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of different treatment policies on survival. Life expectancy increased when transplantation was delayed from the initial stages to intermediate IPSS-R risk (gain-of-life expectancy 5.3, 4.7 and 2.8 years for patients aged ⩽55, 60 and 65 years, respectively), and then decreased for higher risks. Modeling decision analysis on IPSS-R versus original IPSS changed transplantation policy in 29{\%} of patients, resulting in a 2-year gain in life expectancy. In advanced stages, HMAs given before transplant is associated with a 2-year gain-of-life expectancy, especially in older patients. These results provide a preliminary evidence to maximize the effectiveness of allo-SCT in MDS.Leukemia advance online publication, 7 April 2017; doi:10.1038/leu.2017.88.",
author = "{della Porta}, {M. G.} and Jackson, {C. H.} and Alessandrino, {E. P.} and M. Rossi and A. Bacigalupo and {van Lint}, {M. T.} and M. Bernardi and B. Allione and A. Bosi and S. Guidi and V. Santini and L. Malcovati and M. Ubezio and C. Milanesi and E. Todisco and Voso, {M. T.} and P. Musto and F. Onida and Iori, {A. P.} and R. Cerretti and G. Grillo and A. Molteni and P. Pioltelli and L. Borin and E. Angelucci and E. Oldani and S. Sica and C. Pascutto and V. Ferretti and A. Santoro and F. Bonifazi and M. Cazzola and A. Rambaldi",
year = "2017",
doi = "10.1038/leu.2017.88",
language = "English",
volume = "31",
pages = "2449--2457",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

AU - della Porta, M. G.

AU - Jackson, C. H.

AU - Alessandrino, E. P.

AU - Rossi, M.

AU - Bacigalupo, A.

AU - van Lint, M. T.

AU - Bernardi, M.

AU - Allione, B.

AU - Bosi, A.

AU - Guidi, S.

AU - Santini, V.

AU - Malcovati, L.

AU - Ubezio, M.

AU - Milanesi, C.

AU - Todisco, E.

AU - Voso, M. T.

AU - Musto, P.

AU - Onida, F.

AU - Iori, A. P.

AU - Cerretti, R.

AU - Grillo, G.

AU - Molteni, A.

AU - Pioltelli, P.

AU - Borin, L.

AU - Angelucci, E.

AU - Oldani, E.

AU - Sica, S.

AU - Pascutto, C.

AU - Ferretti, V.

AU - Santoro, A.

AU - Bonifazi, F.

AU - Cazzola, M.

AU - Rambaldi, A.

PY - 2017

Y1 - 2017

N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the benefit of cytoreduction before transplant in high-risk patients. We carried out a decision analysis on 1728 MDS who received supportive care, transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised International Prognostic Scoring System (IPSS-R). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of different treatment policies on survival. Life expectancy increased when transplantation was delayed from the initial stages to intermediate IPSS-R risk (gain-of-life expectancy 5.3, 4.7 and 2.8 years for patients aged ⩽55, 60 and 65 years, respectively), and then decreased for higher risks. Modeling decision analysis on IPSS-R versus original IPSS changed transplantation policy in 29% of patients, resulting in a 2-year gain in life expectancy. In advanced stages, HMAs given before transplant is associated with a 2-year gain-of-life expectancy, especially in older patients. These results provide a preliminary evidence to maximize the effectiveness of allo-SCT in MDS.Leukemia advance online publication, 7 April 2017; doi:10.1038/leu.2017.88.

AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the benefit of cytoreduction before transplant in high-risk patients. We carried out a decision analysis on 1728 MDS who received supportive care, transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised International Prognostic Scoring System (IPSS-R). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of different treatment policies on survival. Life expectancy increased when transplantation was delayed from the initial stages to intermediate IPSS-R risk (gain-of-life expectancy 5.3, 4.7 and 2.8 years for patients aged ⩽55, 60 and 65 years, respectively), and then decreased for higher risks. Modeling decision analysis on IPSS-R versus original IPSS changed transplantation policy in 29% of patients, resulting in a 2-year gain in life expectancy. In advanced stages, HMAs given before transplant is associated with a 2-year gain-of-life expectancy, especially in older patients. These results provide a preliminary evidence to maximize the effectiveness of allo-SCT in MDS.Leukemia advance online publication, 7 April 2017; doi:10.1038/leu.2017.88.

UR - http://www.scopus.com/inward/record.url?scp=85017158916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017158916&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.88

DO - 10.1038/leu.2017.88

M3 - Article

AN - SCOPUS:85017158916

VL - 31

SP - 2449

EP - 2457

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -